EUVIMEDEUVIMED entdecken
Crossref

Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2/STAT3 and PI3K/AKT/mTOR signaling

Ali A Albariqi, Dalia A Nawwar, Weam W Ibrahim, Mahmoud M Khattab

International Immunopharmacology · 2026-11 · 188 · 117303

DOI: 10.1016/j.intimp.2026.117303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Immunopharmacology, 2026-11. Verfasst von Ali A Albariqi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Postgraduate program in Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt. Hauptthemen laut MEDLINE: Purines, Sulfonamides, Schizophrenia, Pyrazoles. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Baricitinib, a selective JAK1/JAK2 inhibitor with established anti-inflammatory properties, has demonstrated therapeutic efficacy in several autoimmune and inflammatory diseases. This study aimed to investigate the neuroprotective potential of baricitinib in a ketamine-induced rat model of schizophrenia. Specifically, the study examined its effects on behavioral deficits, neurochemical alterations, and neuroinflammatory responses, while exploring the association of the JAK2/STAT3 and PI3K/AKT/mTOR signaling pathways with its neuroprotective effects. Schizophrenia-like symptoms were induced by intraperitoneal administration of ketamine (30 mg/kg) for five consecutive days, followed by oral treatment with baricitinib (5 or 20 mg/kg/day) for 14 days. Ketamine administration produced significant locomotor hyperactivity, social withdrawal, and cognitive impairment, accompanied by reduced dopamine D2 receptor (D2R), contrary to elevating fibroblast growth factor 9 (FGF9), NLRP3 expression, and pro-inflammatory cytokines including interleukin-1β, interleukin-6, and tumor necrosis factor-α in both the hippocampus and prefrontal cortex. These changes were associated with marked hyperactivation of the JAK2/STAT3 and PI3K/AKT/mTOR pathways. Treatment with baricitinib, particularly at the higher dose (20 mg/kg), significantly attenuated behavioral deficits, restored D2R expression, suppressed FGF9 and NLRP3 levels, reduced pro-inflammatory cytokine production, and normalized aberrant signaling pathway activation. Histological analysis further confirmed preservation of neuronal integrity in both brain regions. These findings indicate that baricitinib exerts robust neuroprotective effects in a ketamine model of schizophrenia, accompanied by attenuation of neuroinflammation and modulation of the JAK/STAT and PI3K/AKT/mTOR pathways. The present results suggest that baricitinib may represent a promising therapeutic candidate for mitigating neuroimmune dysregulation associated with schizophrenia-like alterations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PurinesSulfonamidesSchizophreniaPyrazolesAzetidinesNeuroinflammatory DiseasesNeuroprotective AgentsAnimalsJanus Kinase 2TOR Serine-Threonine KinasesMaleSTAT3 Transcription FactorSignal TransductionProto-Oncogene Proteins c-aktDisease Models, AnimalPhosphatidylinositol 3-KinasesKetamineRatsNLR Family, Pyrin Domain-Containing 3 ProteinRats, Sprague-DawleyBehavior, AnimalHumansCytokines

Stichwörter der Autor:innen

BaricitinibJAK2/STAT3KetamineNeuroinflammationPI3K/AKT/mTORSchizophrenia

Substanzen

PurinesSulfonamidesJanus Kinase 2TOR Serine-Threonine KinasesSTAT3 Transcription FactorProto-Oncogene Proteins c-aktStat3 protein, ratJak2 protein, ratPhosphatidylinositol 3-Kinasesbaricitinib

Autor:innen und Institutionen

  • Postgraduate program in Pharmacology and Toxicology, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt. Electronic address: dalia.nawwar@pharma.cu.edu.eg.
  • Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.

Zitieren

APA

Albariqi, A. A., Nawwar, D. A., Ibrahim, W. W., & Khattab, M. M. (2026). Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2/STAT3 and PI3K/AKT/mTOR signaling. International Immunopharmacology, 188, 117303. https://doi.org/10.1016/j.intimp.2026.117303

Vancouver

Albariqi AA, Nawwar DA, Ibrahim WW, Khattab MM. Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2/STAT3 and PI3K/AKT/mTOR signaling. International Immunopharmacology. 2026;188:117303. doi:10.1016/j.intimp.2026.117303

BibTeX
@article{Albariqi2026,
  author = {Albariqi, Ali A and Nawwar, Dalia A and Ibrahim, Weam W and Khattab, Mahmoud M},
  title = {Baricitinib ameliorates behavioral deficits and NLRP3-related neuroinflammation in a ketamine rat model of schizophrenia: Role of JAK2/STAT3 and PI3K/AKT/mTOR signaling},
  journal = {International Immunopharmacology},
  year = {2026},
  volume = {188},
  pages = {117303},
  doi = {10.1016/j.intimp.2026.117303}
}
Kostenlos starten →